

IN THE CLAIMS

Please cancel claims 1-11 without prejudice toward the continuation of prosecution thereof in a divisional application.

Please cancel claim 12 without prejudice.

Please amend claims 13 and 15 as follows:

scr B1
scr A

13 (Amended). A method of inhibiting the cytocidal effect of TNF without blocking TNF binding to the p75 TNF receptor (residues 27-210 of SEQ ID NO:2), comprising bringing to the vicinity of the p75 TNF receptor a peptide or antibody comprising the antigen binding portion of an antibody which binds to the fourth cysteine rich domain of the p75 TNF receptor, which domain consists of the sequence of amino acid residues 163 to 201 of SEQ ID NO:2, or to the region between said fourth cysteine rich domain of the p75 TNF receptor and the cell membrane, which region consists of the sequence of amino acid residues 201-257 of SEQ ID NO:2

scr A

3 15 (Amended). A method in accordance with claim 13, wherein said peptide or antibody comprises the antigen binding portion of an antibody which binds to the sequence of amino acid residues 201-257 of SEQ ID NO:2.